MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 85 filers reported holding MARINUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $37,431,087 | +9.3% | 4,140,607 | +31.4% | 0.44% | -7.6% |
| Q4 2023 | $34,240,500 | +35.0% | 3,150,000 | 0.0% | 0.47% | +19.4% |
| Q3 2023 | $25,357,500 | -25.9% | 3,150,000 | 0.0% | 0.40% | -14.7% |
| Q2 2023 | $34,209,000 | +57.4% | 3,150,000 | 0.0% | 0.46% | +44.1% |
| Q1 2023 | $21,735,000 | +73.4% | 3,150,000 | 0.0% | 0.32% | +72.2% |
| Q4 2022 | $12,537,000 | -40.2% | 3,150,000 | 0.0% | 0.19% | -51.7% |
| Q3 2022 | $20,948,000 | +37.4% | 3,150,000 | 0.0% | 0.39% | +28.6% |
| Q2 2022 | $15,246,000 | -48.2% | 3,150,000 | 0.0% | 0.30% | -44.1% |
| Q1 2022 | $29,453,000 | -23.4% | 3,150,000 | -2.6% | 0.54% | -17.7% |
| Q4 2021 | $38,432,000 | +4.4% | 3,235,000 | 0.0% | 0.65% | +13.1% |
| Q3 2021 | $36,814,000 | -36.6% | 3,235,000 | 0.0% | 0.58% | -42.8% |
| Q2 2021 | $58,036,000 | +15.9% | 3,235,000 | 0.0% | 1.01% | +16.8% |
| Q1 2021 | $50,078,000 | +27.0% | 3,235,000 | +0.1% | 0.86% | +27.4% |
| Q4 2020 | $39,432,000 | – | 3,232,142 | – | 0.68% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,684,622 | $18,959,000 | 4.18% |
| VR Adviser, LLC | 3,156,803 | $20,993,000 | 3.24% |
| Bleichroeder LP | 1,322,463 | $8,794,000 | 1.84% |
| Granite Point Capital Management, L.P. | 472,056 | $3,139,000 | 1.27% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $9,517,000 | 1.14% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,537,700 | $23,526,000 | 0.98% |
| 683 Capital Management, LLC | 975,000 | $6,484,000 | 0.50% |
| Avoro Capital Advisors LLC | 3,150,000 | $20,948,000 | 0.39% |
| Antara Capital LP | 996,794 | $6,629,000 | 0.18% |
| Woodline Partners LP | 1,368,123 | $9,098,000 | 0.13% |